CHRS logo

CHRS
Coherus Oncology Inc.

5,078
Mkt Cap
$251.43M
Volume
528,982.00
52W High
$2.62
52W Low
$0.71
PE Ratio
-1.31
CHRS Fundamentals
Price
$1.58
Prev Close
$1.63
Open
$1.61
50D MA
$1.74
Beta
1.83
Avg. Volume
959,399.03
EPS (Annual)
-$1.45
P/B
3.20
Rev/Employee
$286,884.35
$48.58
Loading...
Loading...
News
all
press releases
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...
PR Newswire·1d ago
News Placeholder
More News
News Placeholder
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks·10d ago
News Placeholder
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday
Coherus Oncology (NASDAQ:CHRS) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-coherus-biosciences-inc-stock...
MarketBeat·11d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200-Day Moving Average - Here's Why
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving Average - What's Next...
MarketBeat·13d ago
News Placeholder
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?
Here is how Brookdale Senior Living (BKD) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks·29d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average - Time to Sell?
Coherus Oncology (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving Average - Should You Sell...
MarketBeat·29d ago
News Placeholder
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages
Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) has earned an average recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat reports. One...
MarketBeat·1mo ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving Average - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
<
1
2
...
>

Latest CHRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.